INVA

InnovivaA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$30.50

Analysis reference price unavailable

Analysis 2026-09-11 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$24.75

Analysis reference price unavailable

Analysis 2026-09-11 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$15.50

Analysis reference price unavailable

Analysis 2026-09-11 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-11

AI commentary

Primary-source tone is constructive on Q2 revenue growth, IST commercial momentum, stable royalty generation, licensing activity, and share repurchases. Stored secondary coverage reported adjusted EPS of $0.59 versus $0.56 consensus and revenue 5.63% above consensus, but also noted unfavorable pre-release estimate revisions. Exact post-release price reaction and verified subsequent analyst changes are unavailable. Social, options, short-interest, and employee-review coverage is absent, so the zero placeholders in the sentiment object indicate unavailable data rather than neutral readings. Low coverage and unquantified forward milestones warrant cautious monitoring.

RankAlpha Sentiment Codex - 2026-09-11

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-12-31catalystExecution against 2026 IST sales targetHigh impact

Q2 U.S. IST net product sales increased 26% year over year to $36.6 million, and management maintained its target of at least $150 million for 2026. Continued execution toward that threshold would support the operating-growth thesis; a shortfall would challenge it. [#SEC-8K-2026-08-05]

2027-09-11catalystXACDURO international licensing expansionHigh impact

Innoviva announced a distribution and licensing agreement with Dr. Reddy's covering XACDURO in selected international markets. Broader access could support commercial growth, but the available evidence does not quantify economics, launch timing, or expected revenue contribution. [#SEC-8K-2026-08-05]

2027-09-11catalystNortiva Bio platform developmentHigh impact

The wholly owned Nortiva Bio platform adds optionality around long-acting oral medicines, but the packet provides no validated clinical, regulatory, financing, or commercialization milestones. Material value realization therefore remains speculative. [#SEC-8K-2026-08-05]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-11 • Updated nightlySource: Internal modelMethodology